TRex Bio, Inc. TRXB

TRXB Company Overview

TRexBio, Inc. is a privately held biotechnology company focused on developing immunology-based therapeutics that target tissue-resident immune biology. The company operates within the biotechnology and pharmaceutical research industries, with an emphasis on inflammatory, autoimmune, and fibrotic diseases. TRexBio’s platform is designed to identify and characterize tissue-resident regulatory T cells (Tregs) and other immune cell populations in order to discover drug targets that may modulate immune responses with improved precision. Publicly available materials indicate the company uses a combination of computational biology, single-cell genomics, machine learning, and immunology research to support therapeutic discovery.

The company’s primary value drivers are its proprietary discovery platform and its pipeline of immunology-focused therapeutic candidates. TRexBio has positioned itself within a growing segment of precision immunology companies seeking alternatives to broad immunosuppression approaches. The company was founded in 2018 by researchers and biotechnology executives associated with advances in immunology and computational biology. Available public disclosures describe the company as building a differentiated approach centered on tissue-specific immune regulation rather than systemic immune suppression.